Bristol-Myers Squibb and the Dana-Farber Cancer Institute have entered into a research collaboration agreement as part of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the US Dana-Farber Cancer Institute is an academic-based cancer center, and the I-O RPM program is a multi-institutional initiative focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.

As part of the I-O RPM program, Bristol-Myers Squibb and Dana-Farber Cancer Institute will conduct a range of early-phase clinical studies and Bristol-Myers Squibb will support the training of young investigators who contribute to the I-O RPM program at Dana-Farber.

Source: Bristol-Myers Squibb